Dnakor Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.50 Cr
- Revenue Growth %
- Profit Growth -17762.10%
- Ebitda -18539.08%
- Net Worth -3354.82%
- Total Assets 1005.01%
About Dnakor Pharma
Dnakor Pharma Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 October 2020 (Four years and three months 29 days old ). Its registered office is in Mahesana, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹5.50 Cr.
Anandkumar Patel, Dashrathbhai Patel, Babubhai Patel, and Two other members serve as directors at the Company.
Company Details
-
Location
Mahesana, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100GJ2020PTC117356
-
Company No.
117356
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Oct 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Dnakor Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandkumar Patel
|
Director | 15-Oct-2020 | Current |
|
Dashrathbhai Patel
|
Director | 15-Oct-2020 | Current |
|
Babubhai Patel
|
Director | 15-Oct-2020 | Current |
|
Ankitkumar Patel
|
Director | 29-May-2021 | Current |
|
Rajendrakumar Patel
|
Director | 29-May-2021 | Current |
Financial Performance of Dnakor Pharma.
Dnakor Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 17762.1% decrease in profit. The company's net worth observed a substantial decline by a decrease of 3354.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dnakor Pharma?
Unlock access to Dnakor Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹5.50 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 5.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Oct 2021 | State Bank Of India | ₹5.50 Cr | Open |
How Many Employees Work at Dnakor Pharma?
Dnakor Pharma has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dnakor Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dnakor Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
